Evolus Gross Margin 2016-2024 | EOLS
Current and historical gross margin for Evolus (EOLS) over the last 10 years. The current gross profit margin for Evolus as of December 31, 2024 is %.
| Evolus Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2024-12-31 | $0.27B | $0.18B | 68.42% |
| 2024-09-30 | $0.25B | $0.17B | 68.95% |
| 2024-06-30 | $0.24B | $0.16B | 68.78% |
| 2024-03-31 | $0.22B | $0.15B | 68.49% |
| 2023-12-31 | $0.20B | $0.14B | 68.81% |
| 2023-09-30 | $0.19B | $0.13B | 68.65% |
| 2023-06-30 | $0.17B | $0.11B | 66.27% |
| 2023-03-31 | $0.16B | $0.10B | 62.42% |
| 2022-12-31 | $0.15B | $0.09B | 59.73% |
| 2022-09-30 | $0.14B | $0.08B | 57.86% |
| 2022-06-30 | $0.13B | $0.08B | 57.14% |
| 2022-03-31 | $0.12B | $0.07B | 57.38% |
| 2021-12-31 | $0.10B | $0.06B | 56.00% |
| 2021-09-30 | $0.09B | $0.05B | 58.14% |
| 2021-06-30 | $0.08B | $0.05B | 62.34% |
| 2021-03-31 | $0.06B | $0.04B | 66.10% |
| 2020-12-31 | $0.06B | $0.04B | 66.67% |
| 2020-09-30 | $0.06B | $0.04B | 74.55% |
| 2020-06-30 | $0.05B | $0.04B | 74.00% |
| 2020-03-31 | $0.04B | $0.03B | 75.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.779B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||